23andMe Holding Co.

Equities

ME

US90138Q1085

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.4641 ^USD	+1.11%		-3.89%	-49.20%

Apr. 24	23andMe Holding Co. to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology Annual Meeting	CI
Apr. 23	Petros, Lemonaid Health Collaborate to Expand Stendra Availability	MT

23andMe Holding Co. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023

November 08, 2023 at 04:16 pm EST

23andMe Holding Co. reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was USD 50 million compared to USD 75.66 million a year ago. Net loss was USD 75.27 million compared to USD 66.07 million a year ago.
For the six months, sales was USD 110.86 million compared to USD 140.17 million a year ago. Net loss was USD 179.89 million compared to USD 155.6 million a year ago.

Latest news about 23andMe Holding Co.

23andMe Holding Co. to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology Annual Meeting	Apr. 24	CI
Petros, Lemonaid Health Collaborate to Expand Stendra Availability	Apr. 23	MT
Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup	Apr. 18	DJ
US Equity Markets Close Mixed Thursday	Apr. 18	MT
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Apr. 18	MT
Sector Update: Health Care Stocks Ease in Afternoon Trading	Apr. 18	MT
Sector Update: Health Care	Apr. 18	MT
News Highlights : Top Company News of the Day - Thursday at 1 PM ET	Apr. 18	DJ
Top Midday Stories: Taiwan Semiconductor Manufacturing, Blackstone, Elevance Health, D.R. Horton, Infosys and Marsh & McLennan Report Earnings; Tesla's Musk Says Laid-Off Employees Received "Incorrectly Low" Severance; 23andME CEO Mulls Taking Company Private; Northrop Grumman Working with SpaceX on Spy Satellite	Apr. 18	MT
News Highlights : Top Company News of the Day - Thursday at 11 AM ET	Apr. 18	DJ
23andMe CEO Mulls Plan to Take Company Private	Apr. 18	MT
23andMe CEO Mulls Plan to Take Company Private	Apr. 18	MT
23andMe CEO Considering Taking Company Private	Apr. 18	MT
North American Morning Briefing : Stock Futures Rise After TSMC Earnings	Apr. 18	DJ
News Highlights : Top Company News of the Day - Thursday at 5 AM ET	Apr. 18	DJ
News Highlights : Top Company News of the Day - Thursday at 1 AM ET	Apr. 18	DJ
23andMe CEO Wojcicki considering taking firm private, filing shows	Apr. 17	RE
Citigroup Adjusts 23andMe Price Target to $0.47 From $0.85, Maintains Neutral Rating	Apr. 16	MT
23andMe Holding Co. to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research Annual Meeting 2024	Apr. 05	CI
23Andme Holding Co. Announces Management Changes	Mar. 29	CI
Biggest cyberattacks in US healthcare sector	Mar. 20	RE
23andMe Holding Co. Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6	Mar. 20	CI
Transcript : 23andMe Holding Co., Q3 2024 Earnings Call, Feb 07, 2024	Feb. 07
Earnings Flash (ME) 23ANDME Reports Q3 Revenue $44.7M, vs. Street Est of $56.3M	Feb. 07	MT
23andMe Holding Co. Reports Goodwill Impairment for the Third Quarter Ended December 31, 2023	Feb. 07	CI

Chart 23andMe Holding Co.

Duration

Period

More charts

Company Profile

23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customersâ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patientsâ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.

Sector

Healthcare Facilities & Services

Calendar

2024-05-22 - Q4 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

INTERVIEW - Anne Wojcicki, CEO of 23andMe: partnership with Amazon and cancer treatment results

July 13, 2023 at 02:26 pm EDT

More Strategies

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.4641 USD

Average target price

1.425 USD

Spread / Average Target

+207.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
23ANDME HOLDING CO.	-49.20%	224M
SONIC HEALTHCARE LIMITED	-17.89%	8.25B
RADNET, INC.	+39.20%	3.57B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.11%	2.46B
SYNLAB AG	-8.06%	2.46B
DR. LAL PATHLABS LIMITED	-7.35%	2.38B
NEOGENOMICS, INC.	-12.61%	1.81B
FLEURY S.A.	-19.01%	1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.66%	1.21B
METROPOLIS HEALTHCARE LIMITED	+7.56%	1.11B

Medical & Diagnostic Laboratories